PALI

Palisade Bio is a clinical-stage biopharma with a single lever: its lead PDE4-inhibitor prodrug PALI-2108 for inflammatory bowel disease. The filing is explicit that 'our business depends on the successful clinical development, regulatory approval, and commercialization of our lead asset PALI-2108' and that the company 'has never generated any revenues from product sales.' The numbers confirm it — revenue was $0.00 in both FY2024 and FY2025, and net losses have run every year (-$26.6M, -$14.3M, -$12.3M, -$14.4M, -$16.8M FY2021→FY2025). There is no business to value on fundamentals; the equity is a claim on an unproven asset that has only completed a single-center Phase 1 safety/PK/PD study and is just now entering an exploratory Phase 1b, with Phase 2 IND submissions targeted for 2026. Per the rubric this is 'unknowable risk — not investable now.'

The one genuine strength is the balance sheet. October 2025's underwritten offering raised ~$127.6M net, lifting cash to $133M against just $4.96M of total liabilities (liabilities/equity 0.04x) and no meaningful debt. With operating cash burn of only -$10.8M in FY2025, near-term solvency is not the worry. But that capital came at brutal cost to existing holders: shares outstanding exploded to 166M (+3,673% YoY), and management itself flags that 'operations and development of PALI-2108 will require more capital than we currently have' — i.e., more dilution is coming as Phase 2 spend (R&D was already $16.0M) ramps well above the current burn rate.